Breakthrough in Non-Small Cell Lung Cancer Treatment: Akeso Completes First Dosing in Phase III Trial of Ivonescimab Combination Therapy
[City, State] – July 31, 2025 – Akeso, a leading biopharmaceutical company dedicated to developing innovative therapies for challenging diseases, announced today the significant milestone of completing the first dosing in its pivotal Phase III clinical trial. This trial is evaluating the efficacy of ivonescimab, a novel bispecific antibody targeting both PD-1 and VEGF, in combination with chemotherapy, for patients with non-small cell lung cancer (NSCLC) who have developed resistance to prior immunotherapy.
The completion of first dosing marks a crucial step forward in the development of ivonescimab, offering a glimmer of hope for a patient population with limited treatment options. Non-small cell lung cancer is the most prevalent type of lung cancer, and while immunotherapy has revolutionized treatment, a substantial number of patients eventually develop resistance. Addressing this unmet medical need is a key focus for Akeso, and this Phase III trial represents a critical evaluation of ivonescimab’s potential to overcome such resistance.
Ivonescimab’s unique bispecific design allows it to simultaneously block the PD-1 pathway, which is a key mechanism used by cancer cells to evade the immune system, and the VEGF pathway, which is involved in tumor growth and blood vessel formation. This dual mechanism is hypothesized to enhance anti-tumor activity by not only reactivating the immune response but also by targeting the tumor microenvironment, potentially leading to more durable responses in patients who have not benefited from or have relapsed after immunotherapy.
The Phase III trial is a multi-center, randomized, double-blind study designed to rigorously assess the safety and efficacy of the ivonescimab combination therapy compared to a placebo and chemotherapy. The trial aims to enroll a significant number of patients with advanced NSCLC who have demonstrated disease progression after receiving a PD-1 or PD-L1 inhibitor. Key endpoints will include progression-free survival, overall survival, and objective response rate, providing comprehensive data on the treatment’s impact.
“We are incredibly encouraged to announce the completion of first dosing in our Phase III clinical trial of ivonescimab for immunotherapy-resistant NSCLC,” stated [Name and Title of Akeso Spokesperson, if available, otherwise use a generic title like “a representative from Akeso”]. “This milestone underscores our commitment to advancing innovative therapeutic strategies for patients facing difficult-to-treat cancers. The rationale behind ivonescimab’s dual-targeting approach holds great promise for overcoming immunotherapy resistance, and we are eager to see the trial’s results as they become available.”
The development of ivonescimab has been supported by promising preclinical data and encouraging results from earlier-stage clinical trials. The company is working closely with regulatory authorities and clinical investigators to ensure the smooth progression of this important study.
Akeso remains dedicated to its mission of bringing transformative therapies to patients worldwide. The successful completion of first dosing in this Phase III trial represents a significant stride towards potentially offering a new and effective treatment option for individuals battling immunotherapy-resistant non-small cell lung cancer. Further updates on the trial’s progress and findings will be shared as they emerge.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC’ at 2025-07-31 01:46. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.